Vistin Pharma ASA (OSL:VISTN) E10: kr0.80 (As of Mar. 2026)


OSL:VISTN Vistin Pharma ASA OSL:VISTN
80 GF Score
Price kr20.40
GF Value kr25.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA E10?

Vistin Pharma ASA OSL:VISTN 80 E10 is kr0.80 as of Mar. 2026. GuruFocus rates OSL:VISTN with a GF Score™ of 80/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vistin Pharma ASA's adjusted earnings per share data for the three months ended in Mar. 2026 was kr0.480. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr0.80 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vistin Pharma ASA's average E10 Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-06), Vistin Pharma ASA's current stock price is kr20.40. Vistin Pharma ASA's E10 for the quarter that ended in Mar. 2026 was kr0.80. Vistin Pharma ASA's Shiller PE Ratio of today is 25.50.

During the past 13 years, the highest Shiller PE Ratio of Vistin Pharma ASA was 41.03. The lowest was 25.53. And the median was 30.63.


Vistin Pharma ASA  (OSL:VISTN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vistin Pharma ASA's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=20.40/0.80
=25.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Vistin Pharma ASA was 41.03. The lowest was 25.53. And the median was 30.63.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Vistin Pharma ASA E10 Related Terms


Vistin Pharma ASA E10 Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA E10 Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.72 0.79

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.80 0.77 0.79 0.80

OSL:VISTN vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistin Pharma ASA Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's Shiller PE Ratio falls into.


OSL:VISTN
80GF Score
Vistin Pharma ASA OSL:VISTN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vistin Pharma ASA's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.48/141.0300*141.0300
=0.480

Current CPI (Mar. 2026) = 141.0300.

Vistin Pharma ASA Quarterly Data

per share eps CPI Adj_EPS
201606 0.568 103.800 0.772
201609 0.245 104.200 0.332
201612 -0.440 104.400 -0.594
201703 0.230 105.000 0.309
201706 0.330 105.800 0.440
201709 0.190 105.900 0.253
201712 3.390 106.100 4.506
201803 0.340 107.300 0.447
201806 -0.350 108.500 -0.455
201809 -0.070 109.500 -0.090
201812 -1.790 109.800 -2.299
201903 0.040 110.400 0.051
201906 0.010 110.600 0.013
201909 1.340 111.100 1.701
201912 0.090 111.300 0.114
202003 -2.950 111.200 -3.741
202006 0.470 112.100 0.591
202009 0.100 112.900 0.125
202012 0.190 112.900 0.237
202103 0.200 114.600 0.246
202106 0.180 115.300 0.220
202109 0.020 117.500 0.024
202112 0.160 118.900 0.190
202203 -0.340 119.800 -0.400
202206 0.010 122.600 0.012
202209 -0.150 125.600 -0.168
202212 0.380 125.900 0.426
202303 -0.070 127.600 -0.077
202306 0.160 130.400 0.173
202309 0.530 129.800 0.576
202312 0.410 131.900 0.438
202403 0.170 132.600 0.181
202406 0.430 133.800 0.453
202409 0.370 133.700 0.390
202412 0.370 134.800 0.387
202503 0.490 136.100 0.508
202506 0.420 137.800 0.430
202509 0.420 138.500 0.428
202512 0.360 139.100 0.365
202603 0.480 141.030 0.480

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr0.80 mean?
Vistin Pharma ASA (OSL:VISTN) has a E10 of kr0.80 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's E10 too high?
Vistin Pharma ASA's current E10 is kr0.80. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's E10 compare to ZTS and UTHR?
Vistin Pharma ASA's E10 of kr0.80 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current E10 is kr0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (OSL:VISTN) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.40 — trading 20.3% below its estimated fair value. The current E10 is kr0.80. Vistin Pharma ASA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Vistin Pharma ASA (OSL:VISTN), the current E10 is kr0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (OSL:VISTN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.40 is trading 20.3% below its estimated GF Value™ of kr25.61. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for OSL:VISTN:

  • E10: kr0.80
  • GF Value™: kr25.61 vs. price of kr20.40 (20.3% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the OSL:VISTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score

Get the complete analysis for OSL:VISTN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.40
Price
kr25.61
GF Value